USPTO Art Unit 1672 Prosecution Statistics

Art Unit Information

Art Unit: 1672
Group: 1670
Tech Center: 1600
Total Cases: 4,950
Last Active: September 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19322628CAPSID VARIANTS AND METHODS OF USING THE SAMESeptember 2025February 2026Allow510NoNo
19209113CAPSID VARIANTS AND METHODS OF USING THE SAMEMay 2025November 2025Allow610NoNo
19182727VACCINATION OF IMMUNOCOMPROMISED SUBJECTSApril 2025October 2025Allow610YesNo
19182766VACCINATION OF IMMUNOCOMPROMISED SUBJECTSApril 2025September 2025Allow510YesNo
19178522BACTERIOPHAGE COMPOSITIONS AND METHODS FOR TREATMENT OF BACTERIAL INFECTIONSApril 2025November 2025Allow710NoNo
19075180COMPOSITIONS AND METHODSMarch 2025August 2025Allow510NoNo
19035336NEUTRALIZING ANTIBODIES TO GP120 AND THEIR USEJanuary 2025September 2025Allow811NoNo
19031360HERPES ZOSTER mRNA VACCINE, PREPARATION METHOD THEREFOR, AND USE THEREOFJanuary 2025August 2025Allow700NoNo
19006818METHODS FOR USING DUAL GLYCAN BINDING AAV VECTORSDecember 2024July 2025Allow611NoNo
19000377BETACORONAVIRUS mRNA VACCINESDecember 2024December 2025Allow1210NoNo
18938932GALLID ALPHAHERPESVIRUS 3 (MDV-2), A VIRAL VECTOR AGAINST DIFFERENT AVIAN PATHOGENS: A NEW VACCINATION STRATEGY IN THE POULTRY INDUSTRYNovember 2024April 2025Allow500NoNo
18762384BETACORONAVIRUS RNA VACCINESJuly 2024October 2024Allow320YesNo
18748995NOVEL TREATMENT REGIMEN FOR THE TREATMENT OF AUTOIMMUNE DISORDERSJune 2024October 2025Allow1621NoNo
18741683Compositions And Methods Of BDNF ActivationJune 2024January 2026Allow1920NoNo
18738696VACCINE MOLECULESJune 2024June 2025Allow1310NoNo
18734088VIRUS AND ANTIGEN PURIFICATION AND CONJUGATIONJune 2024September 2025Allow1530YesNo
18733545CORONAVIRUS VACCINE COMPRISING A MOSAIC PROTEINJune 2024March 2026Allow2131NoNo
18680187COMPOSITIONS AND METHODS FOR ENHANCING PRODUCTION, GROWTH, SPREAD, OR ONCOLYTIC AND IMMUNOTHERAPEUTIC EFFICACY OF INTERFERON-SENSITIVE VIRUSESMay 2024May 2025Allow1100YesNo
18648166HUMANIZED ANTI-CLAUDIN-1 ANTIBODIES AND USES THEREOFApril 2024February 2026Allow2110NoNo
18630996ENGINEERING AAVApril 2024May 2025Allow1310NoNo
18611550MODIFIED VIRAL PARTICLES FOR GENE THERAPYMarch 2024June 2025Allow1510NoNo
18599308TREATMENT REGIMEN FOR THE TREATMENT OF AUTOIMMUNE DISORDERSMarch 2024November 2025Allow2010NoNo
18443314MICROPOROUS ANNEALED PARTICLE GEL SYSTEMFebruary 2024November 2025Allow2111NoNo
18423395METHODS FOR REDUCING ANERGY IN LYMPHOCYTES USING MODULATORS OF MYCJanuary 2024August 2025Allow1911NoNo
18417465DIAPHRAGM-SPECIFIC NUCLEIC ACID REGULATORY ELEMENTS AND METHODS AND USE THEREOFJanuary 2024November 2025Allow2211NoNo
18403883FLAVIVIRUS VACCINEJanuary 2024September 2025Allow2021NoNo
18390486BROADLY NEUTRALIZING ANTI-HIV-1 ANTIBODIES AND METHODS OF USE THEREOFDecember 2023July 2025Allow1921YesNo
18540621HIV PRE-IMMUNIZATION AND IMMUNOTHERAPYDecember 2023January 2026Allow2611NoNo
18533676Therapeutic Vaccine for Hepatitis B Virus (HBV) using the HBV Core AntigenDecember 2023August 2025Allow2011NoNo
18566986SENSOR FOR DETECTING BIOMARKERS IN A FLUID SAMPLE AND METHODS OF USEDecember 2023November 2025Allow2320YesNo
18527150NUCLEIC ACID VACCINES FOR CORONAVIRUSDecember 2023January 2026Abandon2640YesNo
18526015CORONAVIRUS VACCINE FORMULATIONSDecember 2023June 2025Allow1811NoNo
18506734METHODS FOR MULTI-RESOLUTION ANALYSIS OF CELL-FREE NUCLEIC ACIDSNovember 2023May 2024Allow610NoNo
18503260STABILIZED CORONAVIRUS SPIKE (S) PROTEIN IMMUNOGENS AND RELATED VACCINESNovember 2023August 2025Allow2211YesNo
18503392METHODS FOR MULTI-RESOLUTION ANALYSIS OF CELL-FREE NUCLEIC ACIDSNovember 2023August 2024Allow920YesNo
18479761METHODS OF REDOSING GENE THERAPY VECTORSOctober 2023December 2025Abandon2701NoNo
18478500CUTIBACTERIUM ACNES RECOMBINANT PHAGES ENCODING A HUMAN PROTEINSeptember 2023July 2025Allow2121NoNo
18469130COMPUTATIONAL MODELING OF LOSS OF FUNCTION BASED ON ALLELIC FREQUENCYSeptember 2023June 2024Allow920NoNo
18461241MODIFIED ORTHOPOXVIRUS VECTORSSeptember 2023February 2026Abandon3001NoNo
18239463TYMOVIRUS VIRUS AND VIRUS-LIKE PARTICLES AS NANOCARRIERS FOR IMAGING AND THERAPEUTIC AGENTSAugust 2023December 2025Allow2821NoNo
18452789MARKERS OF ACTIVE HIV RESERVOIRAugust 2023January 2026Abandon2911NoNo
18235432Nucleic Acid Vaccine Composition Comprising a Lipid Formulation, and Method of Increasing the Potency of Nucleic Acid VaccinesAugust 2023September 2025Allow2511NoNo
18234573VARIANT CLASSIFICATION THROUGH HIGH-CONFIDENCE MUTATION DETECTION FROM FLUORESCENCE SIGNALS MEASURED WITH A MULTIPLE MUTATION ASSAYAugust 2023January 2026Allow2900NoNo
18233726SEARCHING OF CHEMICAL STRUCTURESAugust 2023February 2024Allow610YesNo
18366310MUTATED ADENO-ASSOCIATED VIRAL CAPSID PROTEINS FOR CHEMICAL COUPLING OF LIGANDS, NANOPARTICLES OR DRUGS VIA THIOETHER BINDING AND PRODUCTION METHOD THEREOFAugust 2023October 2025Allow2611YesNo
18364884EGG ALLERGY ANTIGENAugust 2023October 2025Allow2712NoNo
18227919POPULATION-BASED IMMUNE RESCUE VIA HERD IMMUNITY MEDIATED BY CELLSJuly 2023April 2024Allow911YesNo
18361787METHODS AND COMPOSITIONS FOR FREEZING AND THAWING MAMMALIAN CELLSJuly 2023January 2026Allow3051YesNo
18350263Devices and Methods for Detecting Microorganisms Using Recombinant Reproduction-Deficient Indicator BacteriophageJuly 2023August 2025Allow2510NoNo
18343685DELIVERY OF THERAPEUTIC RNAS VIA ARRDC1-MEDIATED MICROVESICLESJune 2023March 2026Abandon3311NoNo
18336409Compositions and Methods for Treating Retinal DisordersJune 2023July 2025Allow2511NoNo
18332612Cells selected for high mitochondria and/or reactive oxygen species for use as packaging cells for gene theraphy vectors and viral vaccinesJune 2023January 2026Abandon3142YesNo
17919133DETECTION ASSAYS FOR CORONAVIRUS NEUTRALIZING ANTIBODIESJune 2023September 2025Allow3511YesNo
18330194BROADLY REACTIVE IMMUNOGENS OF DENGUE VIRUS, COMPOSITIONS, AND METHODS OF USE THEREOFJune 2023March 2026Abandon3321NoNo
18206249HBV VACCINEJune 2023September 2025Allow2721NoNo
18324727SPATIALLY ENCODED BIOLOGICAL ASSAYSMay 2023October 2023Allow510NoNo
18324475METHODS AND SYSTEMS FOR PROCESSING A NUCLEIC ACID SAMPLEMay 2023December 2025Abandon3050YesNo
18320297RATIONAL POLYPLOID ADENO-ASSOCIATED VIRUS VECTORS FOR THE TREATMENT OF DISEASEMay 2023November 2025Allow3011NoNo
18036631INFLUENZA VIRUS ENCODING A TRUNCATED NS1 PROTEIN AND A SARS-COV RECEPTOR BINDING DOMAINMay 2023March 2026Allow3410NoNo
18314490BROADLY NEUTRALIZING ANTIBODIES AGAINST HIVMay 2023May 2025Allow2411NoNo
18309475ANTI-RSV MONOCLONAL ANTIBODY FORMULATIONApril 2023December 2025Abandon3131NoNo
18304045SYSTEMS AND METHODS FOR MATCHING MASS SPECTROMETRY DATA WITH A PEPTIDE DATABASEApril 2023October 2023Allow610NoNo
18298529GENE THERAPIES FOR LYSOSOMAL DISORDERSApril 2023November 2025Allow3100NoNo
18297049METHODS, SYSTEMS, AND COMPUTER READABLE MEDIA FOR REPEAT SEQUENCINGApril 2023April 2024Allow1210NoNo
18130166ACTIVATION OF RESIDENT MEMORY T CELLS FOR CANCER IMMUNOTHERAPYApril 2023August 2025Allow2920NoNo
18029437SAR-COV-2 DNA Vaccine and Method of Administering ThereofMarch 2023January 2026Allow3410NoNo
18029576CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS M-SEGMENT NUCLEIC ACID VACCINE AND METHODS OF USE AND PRODUCTIONMarch 2023November 2025Allow3100NoNo
18028613IMPROVED DNA VACCINE FOR SARS-COV-2March 2023March 2026Allow3510NoNo
18184967SYSTEMS AND METHODS FOR DETERMINING NUCLEIC ACIDSMarch 2023January 2024Allow1010YesNo
18185048SYSTEMS AND METHODS FOR DETERMINING NUCLEIC ACIDSMarch 2023June 2024Allow1511YesNo
18181974Separation MethodMarch 2023June 2025Allow2820NoNo
18180760LENTIVIRAL VECTORS FOR DELIVERY OF PKLR TO TREAT PYRUVATE KINASE DEFICIENCYMarch 2023August 2025Allow2911NoNo
18119030SYSTEM AND METHOD FOR GENOMIC ASSOCIATIONMarch 2023August 2023Allow611NoNo
18042913NOVEL CORONAVIRUS RECOMBINANT SPIKE PROTEIN, POLYNUCLEOTIDE ENCODING SAME, VECTOR COMPRISING POLYNUCLEOTIDE, AND VACCINE FOR PREVENTING OR TREATING CORONAVIRUS INFECTION, COMPRISING VECTORFebruary 2023March 2026Allow3620NoNo
18042637COVID-19 VACCINES WITH TOCOPHEROL-CONTAINING SQUALENE EMULSION ADJUVANTSFebruary 2023March 2026Abandon3710NoNo
18173618COMPOSITIONS AND METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS)February 2023October 2025Abandon3211NoNo
18172957Methods and Systems for Analyzing Nucleic Acid MoleculesFebruary 2023November 2023Abandon920YesNo
18022488CIRCULAR RNA VACCINES AND METHODS OF USE THEREOFFebruary 2023March 2026Allow3710NoNo
18020797FUSION PROTEINS COMPRISING SARS-COV-2 NUCLEOCAPSID DOMAINSFebruary 2023September 2025Allow3100NoNo
18167804Methods and Systems for Analyzing Nucleic Acid MoleculesFebruary 2023January 2024Allow1111YesNo
18166151SYSTEMS TO PRODUCE B CELLS GENETICALLY MODIFIED TO EXPRESS SELECTED ANTIBODIESFebruary 2023November 2025Allow3421NoNo
18164988HIV-1 ENV FUSION PEPTIDE IMMUNOGENS AND THEIR USEFebruary 2023July 2025Allow2921NoNo
18164942RECOMBINANT AAV1, AAV5, AND AAV6 CAPSID MUTANTS AND USES THEREOFFebruary 2023November 2025Abandon3421NoNo
18040617Neutralizing Antibodies that Bind the SARS-COV-2 S ProteinFebruary 2023March 2026Abandon3701NoNo
18161046MATERIALS AND METHODS FOR IMPROVING IMMUNE RESPONSES AND SKIN AND/OR MUCOSAL BARRIER FUNCTIONSJanuary 2023August 2025Allow3111YesNo
18017677BIG DATA-BASED INTELLIGENT ALGORITHM FOR INTRAORAL PROSTHESIS DESIGN SCHEMEJanuary 2023December 2023Allow1120YesNo
18100074SYSTEMS AND METHODS FOR REMOVING HUMAN GENETIC DATA FROM GENETIC SEQUENCESJanuary 2023October 2023Allow910YesNo
18017374INFLUENZA VIRUS BACKBONEJanuary 2023October 2025Allow3300NoNo
18155523METHODS FOR MULTI-RESOLUTION ANALYSIS OF CELL-FREE NUCLEIC ACIDSJanuary 2023October 2023Allow910NoNo
18154278RECOMBINANT ARTERIVIRUS REPLICON SYSTEMS AND USES THEREOFJanuary 2023September 2024Allow2010NoNo
18005291RECOMBINANT POXVIRIDAE VECTOR EXPRESSING CO-STIMULATORY MOLECULESJanuary 2023January 2026Allow3610NoNo
18005027Method for the Production of AAVJanuary 2023January 2026Allow3620NoNo
18004494Nucleoside-modified RNA for Inducing an Immune Response Against SARS-CoV-2January 2023March 2026Allow3811NoNo
18150201PREDICTING METHOD OF CELL DECONVOLUTION BASED ON A CONVOLUTIONAL NEURAL NETWORKJanuary 2023April 2024Abandon1620NoNo
18149482VACCINE COMBINATION AGAINST SARS-COV-2 AND METHOD FOR PREVENTING INFECTION OF SARS-COV-2January 2023March 2026Abandon3810NoNo
18013863PERSISTENT MEMORY T-CELL RESPONSES TO CANCER AND INFECTIOUS-DISEASE ANTIGENS BY MANIPULATION OF AMINO ACID-CATABOLISM PATHWAYSDecember 2022November 2025Allow3510NoNo
18146508COMPOSITIONS AND METHODS TO DETECT ADENOVIRUS NUCLEIC ACIDS AND METAPNEUMOVIRUS AND/OR RHINOVIRUS NUCLEIC ACIDSDecember 2022June 2025Allow3011NoNo
18012366THERAPEUTIC RNA FOR HPV-POSITIVE CANCERDecember 2022December 2025Allow3610NoNo
18068782Compositions, Kits, and Systems for the Rapid Detection of Bacteria Using Recombinant Bacteriophage to Express an Indicator SubunitDecember 2022September 2025Allow3321NoNo
18085269MULTIPARAMETRIC DISCOVERY AND OPTIMIZATION PLATFORMDecember 2022October 2023Allow1010YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1672.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
36
Examiner Affirmed
24
(66.7%)
Examiner Reversed
12
(33.3%)
Reversal Percentile
53.8%
Higher than average

What This Means

With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
268
Allowed After Appeal Filing
93
(34.7%)
Not Allowed After Appeal Filing
175
(65.3%)
Filing Benefit Percentile
61.9%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 34.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Art Unit 1672 - Prosecution Statistics Summary

Executive Summary

Art Unit 1672 is part of Group 1670 in Technology Center 1600. This art unit has examined 4,950 patent applications in our dataset, with an overall allowance rate of 80.6%. Applications typically reach final disposition in approximately 25 months.

Comparative Analysis

Art Unit 1672's allowance rate of 80.6% places it in the 65% percentile among all USPTO art units. This art unit has an above-average allowance rate compared to other art units.

Prosecution Patterns

Applications in Art Unit 1672 receive an average of 1.63 office actions before reaching final disposition (in the 29% percentile). The median prosecution time is 25 months (in the 76% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more favorable examination environment compared to the USPTO average.
  • With fewer office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is shorter than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.